Podcast: TRK fusion-positive GI cancers
In this NTRK CONNECT podcast Prof Frédérique Penault-Llorca and Prof Andrea Sartore-Bianchi discuss the detection and management of TRK fusion-positive GI cancers.
Prof Frederique Penault-Llorca's portrait

Prof Frédérique Penault-Llorca

University of Clermont-Ferrand

Prof Andrea Sartore-Bianchi's portrait

Prof Andrea Sartore-Bianchi

Niguarda Cancer Centre
Milan, Italy

Simply click on the episode below to listen here:

This HCC CONNECT podcast is also available on
Castos, Spotify, Apple Podcasts, and Google Podcasts.

In the GI episode, Prof Frédérique Penault-Llorca and Prof Andrea Sartore-Bianchi provide a summary and share their personal experiences about the diagnosis and treatment of TRK fusion-positive GI cancer.

Prof Sartore-Bianchi provides an overview of NTRK genes and the biology of NTRK fusions, including their role as a driver of oncogenesis. He then provides a concise summary of the approved TRK inhibitor therapies, larotrectinib and entrectinib, emphasising the expanding dataset showing high response rates and durable responses seen in patients with GI cancers.

Prof Penault-Llorca outlines the challenges pathologists face detecting the extremely rare NTRK fusions in GI cancers, providing a summary of the range of tools available to detect them and offering her perspectives on an enrichment strategy for GI cancers, especially colorectal cancer.

They conclude by emphasising the importance of not missing any patients, through applying enrichment strategies that can enhance the likelihood of finding NTRK fusions. In doing so, more patients will be able to benefit from the proven efficacy of TRK inhibitor therapy.

Podcast Transcript

Frédérique Penault-Llorca

Today, with Andrea we are going to go through the diagnosis and treatment of NTRK fusion-positive GI cancers. Andrea, what are the NTRK genes, and what about the NTRK fusion; why are they so interesting to look at in GI cancers?

Andrea Sartore-Bianchi

Yes, thank you Frédérique, and indeed we know the gene fusions can be a driver of oncogenesis, but it is now when we are seeing very important advances in clinical sequencing technologies that we are aware of new…